ADVM · As filed with the SEC
Adverum Biotechnologies balance sheet, by quarter
The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 26,060 | 42,418 | 49,161 | 60,652 |
| Short-term investments | 0 | 1,979 | 33,922 | 65,039 |
| Prepaid expenses and other current assets | 2,849 | 3,994 | 6,386 | 5,609 |
| Total current assets | 28,909 | 48,391 | 89,469 | 131,300 |
| Operating lease right-of-use assets | 29,031 | 33,529 | 33,584 | 33,611 |
| Property and equipment, net | 10,462 | 10,811 | 11,135 | 11,607 |
| Restricted cash | 1,976 | 1,976 | 1,976 | 1,976 |
| Deposit and other long-term assets | 2,023 | 1,472 | 1,490 | 1,347 |
| Total assets | 72,401 | 96,179 | 137,654 | 179,841 |
| Liabilities and stockholders’ (deficit) equity | ||||
| Current liabilities: | ||||
| Accounts payable | 12,459 | 4,748 | 1,819 | 1,610 |
| Accrued expenses and other current liabilities | 26,476 | 19,245 | 16,046 | 15,620 |
| Lease liability, current portion | 5,814 | 7,363 | 7,229 | 5,668 |
| Total current liabilities | 44,749 | 31,356 | 25,094 | 22,898 |
| Lease liability, net of current portion | 83,126 | 84,858 | 85,949 | 86,037 |
| Other non-current liabilities | 179 | 184 | 189 | 192 |
| Total liabilities | 128,054 | 116,398 | 111,232 | 109,127 |
| Stockholders’ (deficit) equity: | ||||
| Preferred stock | 0 | 0 | 0 | 0 |
| Common stock | 2 | 2 | 2 | 2 |
| Additional paid-in capital | 1,155,598 | 1,143,391 | 1,140,848 | 1,138,070 |
| Accumulated other comprehensive loss | (440) | (451) | (458) | (407) |
| Accumulated deficit | (1,210,813) | (1,163,161) | (1,113,970) | (1,066,951) |
| Total stockholders’ (deficit) equity | (55,653) | (20,219) | 26,422 | 70,714 |
| Total liabilities and stockholders’ (deficit) equity | 72,401 | 96,179 | 137,654 | 179,841 |
| Common stock, shares issued (in shares) | — | — | — | 20,848 |
| Common stock, shares outstanding (in shares) | — | — | — | 20,848 |
| Common stock, shares authorized (in shares) | — | — | — | 300,000 |
| Common stock, par value (in USD per share) | — | — | — | 0.00 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.